This study is about testing a medicine called Deucravacitinib for people with Systemic Lupus Erythematosus (SLE). SLE is a condition where the body’s defense system attacks its own tissues. The study compares Deucravacitinib with a placebo (a harmless pill that has no medicine) to see which works better and is safer.
To join, you must have SLE for at least 24 weeks and meet certain health criteria. You need to be on SLE treatment for at least 12 weeks. If you have other autoimmune diseases, serious infections, or specific health conditions, you cannot join.
- Duration: The study will require regular visits and monitoring, but the exact length is not specified here.
- Participation: You must have a stable dose of SLE medicine before joining and during the study.
- Risks: You cannot join if you have serious infections or other autoimmune diseases.
This study helps researchers find better treatments for SLE. Talk to your doctor to see if it’s right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand